Kronos Bio (KRON)
(Delayed Data from NSDQ)
$0.99 USD
-0.01 (-1.40%)
Updated Sep 4, 2024 04:00 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Income Statements
Fiscal Year end for Kronos Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 6 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 6 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 128 | 137 | 151 | 58 | 17 |
Income After Depreciation & Amortization | -122 | -137 | -151 | -58 | -17 |
Non-Operating Income | 9 | 4 | 0 | -27 | 1 |
Interest Expense | 0 | 0 | 0 | 4 | 0 |
Pretax Income | -113 | -133 | -151 | -88 | -16 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -113 | -133 | -151 | -88 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -113 | -133 | -151 | -88 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -122 | -135 | -145 | -57 | -16 |
Depreciation & Amortization (Cash Flow) | 0 | 2 | 6 | 1 | 0 |
Income After Depreciation & Amortization | -122 | -137 | -151 | -58 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 57.74 | 56.20 | 54.75 | 16.28 | NA |
Diluted EPS Before Non-Recurring Items | -1.95 | -2.37 | -2.76 | -3.75 | NA |
Diluted Net EPS (GAAP) | -1.95 | -2.37 | -2.76 | -5.43 | NA |
Fiscal Year end for Kronos Bio, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 2.69 | 2.52 | 2.29 | 0.92 | 1.86 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 2.69 | 2.52 | 2.29 | 0.92 | 1.86 |
SG&A, R&D, and Dept/Amort Expenses | 20.72 | 34.51 | 29.63 | 34.74 | 34.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | -18.03 | -31.99 | -27.34 | -33.82 | -32.17 |
Non-Operating Income | 1.82 | 2.04 | 2.02 | 2.45 | 2.43 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -16.20 | -29.96 | -25.32 | -31.37 | -29.74 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -16.20 | -29.96 | -25.32 | -31.37 | -29.74 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -16.20 | -29.96 | -25.32 | -31.37 | -29.74 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 60.10 | 59.52 | 58.27 | 58.15 | 57.40 |
Diluted EPS Before Non-Recurring Items | -0.27 | -0.50 | -0.43 | -0.54 | -0.52 |
Diluted Net EPS (GAAP) | -0.27 | -0.50 | -0.43 | -0.54 | -0.52 |